Palbonamo 125 mg contains Palbociclib, an oral anticancer medicine used in the treatment of breast cancer. It belongs to the class of CDK4/6 inhibitors and is mainly prescribed for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer in combination with hormonal therapy. Palbociclib helps slow the growth of cancer cells and delay disease progression.
Mechanism of action:
Palbociclib blocks the activity of cyclin-dependent kinases 4 and 6 (CDK4/6). These enzymes are essential for cancer cells to progress from the G1 phase to the S phase of the cell cycle (cell division). By inhibiting CDK4/6, Palbonamo stops cancer cells from dividing and proliferating, slowing tumor growth.
Uses:
-
Advanced or metastatic HR+, HER2-negative breast cancer
-
Used in combination with aromatase inhibitors or fulvestrant as part of hormone therapy
-
Helps delay disease progression and improve patient outcomes
Adverse effects:
Common side effects include low blood cell counts (neutropenia, anemia, thrombocytopenia), fatigue, nausea, diarrhea, hair thinning, mouth sores, and infections. Serious but less common effects include severe infections due to immune suppression, liver function abnormalities, and rare lung problems.
